1. Home
  2. ATYR vs ALOT Comparison

ATYR vs ALOT Comparison

Compare ATYR & ALOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • ALOT
  • Stock Information
  • Founded
  • ATYR 2005
  • ALOT 1969
  • Country
  • ATYR United States
  • ALOT United States
  • Employees
  • ATYR N/A
  • ALOT N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • ALOT Computer peripheral equipment
  • Sector
  • ATYR Health Care
  • ALOT Technology
  • Exchange
  • ATYR Nasdaq
  • ALOT Nasdaq
  • Market Cap
  • ATYR 126.3M
  • ALOT 110.1M
  • IPO Year
  • ATYR 2015
  • ALOT N/A
  • Fundamental
  • Price
  • ATYR $1.94
  • ALOT $13.88
  • Analyst Decision
  • ATYR Strong Buy
  • ALOT
  • Analyst Count
  • ATYR 4
  • ALOT 0
  • Target Price
  • ATYR $19.25
  • ALOT N/A
  • AVG Volume (30 Days)
  • ATYR 487.7K
  • ALOT 17.6K
  • Earning Date
  • ATYR 11-07-2024
  • ALOT 12-04-2024
  • Dividend Yield
  • ATYR N/A
  • ALOT N/A
  • EPS Growth
  • ATYR N/A
  • ALOT 591.76
  • EPS
  • ATYR N/A
  • ALOT 0.83
  • Revenue
  • ATYR $588,000.00
  • ALOT $150,643,000.00
  • Revenue This Year
  • ATYR N/A
  • ALOT N/A
  • Revenue Next Year
  • ATYR $2,057.88
  • ALOT N/A
  • P/E Ratio
  • ATYR N/A
  • ALOT $15.97
  • Revenue Growth
  • ATYR N/A
  • ALOT 0.29
  • 52 Week Low
  • ATYR $1.08
  • ALOT $11.79
  • 52 Week High
  • ATYR $2.50
  • ALOT $18.83
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 60.32
  • ALOT 50.81
  • Support Level
  • ATYR $1.83
  • ALOT $13.09
  • Resistance Level
  • ATYR $1.96
  • ALOT $13.56
  • Average True Range (ATR)
  • ATYR 0.08
  • ALOT 0.47
  • MACD
  • ATYR 0.02
  • ALOT 0.03
  • Stochastic Oscillator
  • ATYR 93.10
  • ALOT 76.14

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About ALOT AstroNova Inc.

AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.

Share on Social Networks: